Low-Dose Decitabine for Patients With Thrombocytopenia Following Allogeneic Hematopoietic Stem Cell Transplantation: A Pilot Therapeutic Study

JAMA Oncol. 2015 May;1(2):249-51. doi: 10.1001/jamaoncol.2014.316.

Authors

Yue Han¹, Yaqiong Tang¹, Jia Chen¹, Jianying Liang¹, Chunmei Ye¹, Changgeng Ruan¹, Depei Wu¹

Affiliation

¹ Jiangsu Institute of Hematology, Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, The First Affiliated Hospital of Soochow University, Suzhou, China2Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.

PMID: 26181032
DOI: 10.1001/jamaoncol.2014.316

No abstract available

Publication types

Controlled Clinical Trial
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Azacitidine / administration & dosage
Azacitidine / analogs & derivatives*
Blood Platelets / drug effects*
Bone Marrow Examination
China
Decitabine
Hematopoietic Stem Cell Transplantation / adverse effects*
Humans
Pilot Projects
Platelet Count
Thrombocytopenia / blood
Thrombocytopenia / diagnosis
Thrombocytopenia / drug therapy*
Thrombocytopenia / etiology
Time Factors
Transplantation, Homologous
Treatment Outcome

Substances

Decitabine
Azacitidine